Prosecution Of Crimes Related To Counterfeit Medicines
Background on Counterfeit Medicines in Nepal
Legal Framework:
Drugs Act, 1978 (Amended 2035 BS and 2076 BS): Prohibits manufacturing, selling, or distributing counterfeit or substandard drugs.
Nepalese Penal Code (1962, amended 2017): Sections on fraud, adulteration, and public endangerment can apply.
Consumer Protection Act: Supports prosecution of businesses causing harm to public health.
Definition: Counterfeit medicines include fake drugs, substandard formulations, or misbranded products sold in Nepalese markets.
Penalty: Depending on severity, imprisonment, fines, and revocation of licenses.
Case 1: Kathmandu Valley Fake Antibiotics Case (2019)
Facts:
Police raided a warehouse distributing counterfeit antibiotics.
Medicines lacked proper registration numbers and were manufactured in an unlicensed facility.
Hundreds of patients received ineffective or harmful medication.
Legal Issues:
Violation of Drugs Act Sections 19 and 20 (production and sale of unregistered drugs).
Liability for public endangerment under the Penal Code.
Outcome:
Two warehouse operators and one pharmacist were arrested and remanded.
Convicted of manufacturing and distributing counterfeit drugs; received 2 years imprisonment and fines of NPR 500,000 each.
Significance:
Reinforced strict liability of distributors and pharmacists.
Showed that authorities can prosecute beyond just the manufacturer, including supply chain actors.
Case 2: Fake Ayurvedic Medicines Case – Lalitpur (2020)
Facts:
Ayurvedic medicines sold online and in local shops were found to be counterfeit.
Labels claimed ingredients not present in the product.
Legal Issues:
Misbranding and fraud under Consumer Protection Act.
Unregistered production violating Drugs Act 1978.
Outcome:
Court fined the shop owner NPR 200,000 and suspended the shop license.
Two online sellers were convicted in absentia; their website blocked.
Significance:
First notable case targeting e-commerce sale of counterfeit medicines in Nepal.
Showed that regulatory enforcement now includes digital platforms.
Case 3: Fake Painkillers Seizure in Birgunj (2018)
Facts:
Customs seized a consignment of counterfeit painkillers at the border.
The drugs were labeled as imported from India but manufactured domestically.
Legal Issues:
Import/export violations and fraud.
Potential endangerment to human health.
Outcome:
Importer arrested; case filed under Customs Act 2064 BS and Drugs Act.
Court imposed 3 years imprisonment and ordered destruction of all seized products.
Significance:
Showed coordination between customs, police, and Department of Drug Administration (DDA).
Reinforced criminal liability for cross-border counterfeit medicine trafficking.
Case 4: Counterfeit Cancer Drugs Case – Bhaktapur (2021)
Facts:
Cancer patients received substandard chemotherapy drugs from a private hospital pharmacy.
Hospital staff claimed drugs were purchased from licensed distributors.
Legal Issues:
Violation of Drugs Act 1978, Sections 19 and 20 (sale of substandard drugs).
Negligence leading to potential fatal consequences.
Outcome:
Pharmacy manager charged; hospital director held partially liable.
Court ruled 6 months imprisonment for manager, fine of NPR 400,000, and mandated DDA monitoring.
Significance:
First major case involving life-threatening counterfeit drugs in hospital settings.
Reinforced the responsibility of healthcare institutions in verifying authenticity.
Case 5: Fake Pediatric Syrup Case – Dang District (2017)
Facts:
Parents reported adverse reactions in children after administration of pediatric syrup.
Investigation revealed the syrup was counterfeit, lacking proper dosing information.
Legal Issues:
Fraud, adulteration, and violation of Drugs Act 1978.
Potential liability under Penal Code Section 180 (negligent harm to public health).
Outcome:
Manufacturer arrested; two distributors prosecuted.
Sentences: 18 months imprisonment for manufacturer, fines for distributors.
Significance:
Highlighted the public health risk of counterfeit medicines for vulnerable populations (children).
Demonstrated that investigation often starts from consumer complaints.
Case 6: Counterfeit Heart Medication Case – Pokhara (2022)
Facts:
Counterfeit heart medications (beta-blockers) were seized from pharmacies.
Patients had complaints of ineffective treatment.
Legal Issues:
Sale of unregistered drugs, misbranding, endangering human life.
Accountability of pharmacists under Drugs Act Section 20.
Outcome:
Pharmacy owner and supplier arrested; courts imposed 2-year imprisonment and fines.
Products destroyed under court supervision.
Significance:
Emphasized shared liability of supplier and retailer.
Reinforced DDA’s authority to inspect pharmacies proactively.
Case 7: E-Commerce Fake Medicine Network (2023)
Facts:
Online platform sold counterfeit antibiotics and antiviral drugs during pandemic.
Many consumers unknowingly bought fake medicine.
Legal Issues:
Violation of Drugs Act and Consumer Protection Act.
Organized crime involvement due to networked sale.
Outcome:
Four suspects arrested; court imposed fines totaling NPR 1 million.
Website blocked; DDA instructed e-commerce monitoring.
Significance:
First case addressing digital sale of counterfeit medicines in Nepal.
Highlighted increasing challenges in controlling online medicine fraud.
Synthesis and Key Takeaways
Legal Provisions Used:
Drugs Act 1978: Sections on manufacturing, sale, and distribution of fake medicines.
Penal Code: Sections on fraud, negligence, and public endangerment.
Consumer Protection Act: Misbranding and consumer fraud.
Common Features Across Cases:
Involvement of manufacturers, distributors, and retailers.
Often discovered via consumer complaints, police raids, or customs checks.
Courts imposed imprisonment, fines, and destruction of drugs.
Challenges in Prosecution:
Establishing the origin of counterfeit drugs.
Digital sale of medicines complicates jurisdiction.
Coordinating across police, DDA, and customs authorities.
Judicial Trend:
Courts in Nepal take counterfeit medicine cases seriously due to public health risk.
Liability is strict and can extend to all actors in the supply chain.
RELATED Blog
comments